<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Santarelli, Lory</style></author><author><style face="normal" font="default" size="100%">Staffolani, Sara</style></author><author><style face="normal" font="default" size="100%">Strafella, Elisabetta</style></author><author><style face="normal" font="default" size="100%">Nocchi, Linda</style></author><author><style face="normal" font="default" size="100%">Manzella, Nicola</style></author><author><style face="normal" font="default" size="100%">Grossi, Paola</style></author><author><style face="normal" font="default" size="100%">Bracci, Massimo</style></author><author><style face="normal" font="default" size="100%">Pignotti, Elettra</style></author><author><style face="normal" font="default" size="100%">Alleva, Renata</style></author><author><style face="normal" font="default" size="100%">Borghi, Battista</style></author><author><style face="normal" font="default" size="100%">Pompili, Cecilia</style></author><author><style face="normal" font="default" size="100%">Sabbatini, Armando</style></author><author><style face="normal" font="default" size="100%">Rubini, Corrado</style></author><author><style face="normal" font="default" size="100%">Zuccatosta, Lina</style></author><author><style face="normal" font="default" size="100%">Bichisecchi, Elisabetta</style></author><author><style face="normal" font="default" size="100%">Valentino, Matteo</style></author><author><style face="normal" font="default" size="100%">Horwood, Keith</style></author><author><style face="normal" font="default" size="100%">Comar, Manola</style></author><author><style face="normal" font="default" size="100%">Bovenzi, Massimo</style></author><author><style face="normal" font="default" size="100%">Dong, Lan-Feng</style></author><author><style face="normal" font="default" size="100%">Neuzil, Jiri</style></author><author><style face="normal" font="default" size="100%">Amati, Monica</style></author><author><style face="normal" font="default" size="100%">Tomasetti, Marco</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.</style></title><secondary-title><style face="normal" font="default" size="100%">Lung Cancer</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Lung Cancer</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 Sep 25</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">ENG</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;OBJECTIVES: &lt;/b&gt;Malignant mesothelioma (MM) is a highly aggressive tumor with poor prognosis. A major challenge is the development and application of early and highly reliable diagnostic marker(s). Serum biomarkers, such as 'soluble mesothelin-related proteins' (SMRPs), is the most studied and frequently used in MM. However, the low sensitivity of SMRPs for early MM limits its value; therefore, additional biomarkers are required. In this study, two epigenetically regulated markers in MM (microRNA-126, miR-126, and methylated thrombomodulin promoter, Met-TM) were combined with SMRPs and evaluated as a potential strategy to detect MM at an early stage.&lt;/p&gt;&lt;p&gt;&lt;b&gt;MATERIALS AND METHODS: &lt;/b&gt;A total of 188 subjects, including 45 MM patients, 99 asbestos-exposed subjects, and 44 healthy controls were prospectively enrolled, serum samples collected, and serum levels of SMRPs, miR-126 and Met-TM evaluated. Logistic regression analysis was performed to evaluate the diagnostic value of the three biomarkers. Using this approach, the performance of the '3-biomarker classifier' was tested by calculating the overall probability score of the MM and control samples, respectively, and the ROC curve was generated.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS AND CONCLUSION: &lt;/b&gt;The combination of the three biomarkers was the best predictor to differentiate MM patients from asbestos-exposed subjects and healthy controls. The accuracy and cancer specificity was confirmed in a second validation cohort and lung cancer population. We propose that the combination of the two epigenetic biomarkers with SMRPs as a diagnosis for early MM overcomes the limitations of using SMRPs alone.&lt;/p&gt;</style></abstract><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/26431916?dopt=Abstract</style></custom1></record></records></xml>